Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Dermatomyositis (SCGAM-02)
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2018
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 13 Dec 2018 This trial has been completed in Czech Republic , according to European Clinical Trials Database.
- 04 Dec 2018 This trial was discontinued in Hungary (End date: 2018-12-15), according to European Clinical Trials Database.
- 22 Nov 2018 This trial was discontinued in Germany, according to European Clinical Trials Database.